Parkinson's Blog

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 study suggesting a potential role for GLP-1 agonists in PD.

The conductor, 82, today confirms a long-suspected diagnosis…

The US Food and Drug Administration (FDA) rejected three prior regulatory applications before granting approval.

The full results of the Exenatide-PD3 study, a phase 3 clinical trial of Type 2 diabetes drug exenatide (Bydureon), have now been published. They report

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson’s disease. The US FDA this week approved the sale of the treatment, which harnesses innovative technology to make managing the condition easier and more impactful, will be available towards the end of 2025.

New Delhi, Feb 4 (IANS) The global Parkinson’s disease (PD) market is expected to grow to $7.9 billion…

/PRNewswire/ — A report released today by The National Alliance for Caregiving (NAC), with support from The Michael J. Fox Foundation for Parkinson’s Research…

Works by 118 artists, on show at Bonhams, will be sold in aid of the Cure3 initiative

We look back at some of area’s best stories of the week.

Manchester’s Royal Northern School of Music sees composers write music inspired by those with the disease.